CoChat

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Open access
Nicholls, Stephen J., Nelson, Adam J., Ditmarsch, Marc, Kastelein, John J.P., Ballantyne, Christie M., Ray, Kausik K., Navar, Ann Marie, Nissen, Steven E., Harada-Shiba, Mariko, Curcio, Danielle L., Neild, Annie, Kling, Douglas, Hsieh, Andrew, Butters, Julie, Ference, Brian A., Laufs, Ulrich, Banach, Maciej, Mehran, Roxana, Catapano, Alberico L., Huo, Yong, Szarek, Michael, Balinskaite, Violeta, Davidson, Michael H. · 2025 · New England Journal of Medicine
Cited by 103

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events. METHODS: We conducted a multinational, randomized, placebo-controlled trial involving patients with heterozygous familial hypercholesterolemia or a history of atherosclerotic cardiovascular disease who were receiving maximum tolerated doses of lipid-lowering therapy. Patients with an LDL cholesterol level of 100 mg per deciliter or higher or a non-high-density lipoprotein (HDL) cholesterol level of 130 mg per deciliter or higher, as well as those with an LDL cholesterol level of 55 to 100 mg per deciliter or a non-HDL cholesterol level of 85 to 130 mg per deciliter and at least one additional cardiovascular risk factor, were eligible for inclusion. The patients were randomly assigned in a 2:1 ratio to receive either 10 mg of obicetrapib once daily or matching placebo for 365 days. The primary end point was the percent change in the LDL cholesterol level from baseline to day 84. RESULTS: A total of 2530 patients underwent randomization; 1686 patients were assigned to receive obicetrapib and 844 to receive placebo. The mean age of the patients was 65 years, 34% were women, and the mean baseline LDL cholesterol level was 98 mg per deciliter. The least-squares mean percent change from baseline to day 84 in the LDL cholesterol level was -29.9% (95% confidence interval [CI], -32.1 to -27.8) in the obicetrapib group, as compared with 2.7% (95% CI, -0.4 to 5.8) in the placebo group, for a between-group difference of -32.6 percentage points (95% CI, -35.8 to -29.5; P<0.001). The incidence of adverse events appeared to be similar in the two groups. CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were receiving maximum tolerated doses of lipid-lowering therapy and were at high risk for cardiovascular events, obicetrapib reduced LDL cholesterol levels by 29.9%. (Funded by NewAmsterdam Pharma; BROADWAY ClinicalTrials.gov number, NCT05142722.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2415820

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 13

  1. 10.1016/j.jacc.2022.02.048 · DOI · Paper page
  2. 10.1016/j.lanepe.2023.100624 · DOI · Paper page
  3. 10.1001/jamacardio.2021.1810 · DOI · Paper page
  4. 10.1111/bcp.12380 · DOI
  5. 10.1016/S0140-6736(15)60158-1 · DOI · Paper page
  6. 10.1038/s41591-022-01936-7 · DOI · Paper page
  7. 10.1016/j.jacl.2023.05.098 · DOI · Paper page
  8. 10.5551/jat.64828 · DOI
  9. 10.1016/j.ahj.2024.05.002 · DOI
  10. 10.1016/j.jacl.2023.03.006 · DOI
  11. 10.1007/s11883-022-01070-2 · DOI
  12. 10.1093/eurheartj/ehab863 · DOI
  13. 10.1093/cvr/cvab350 · DOI

Cited by

See all 103

Metadata

Authors
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Navar, A. M., Nissen, S. E., Harada-Shiba, M., Curcio, D. L., Neild, A., Kling, D., Hsieh, A., Butters, J., Ference, B. A., Laufs, U., Banach, M., Mehran, R., Catapano, A. L., Huo, Y., Szarek, M., Balinskaite, V., & Davidson, M. H.
Venue
New England Journal of Medicine
Published
2025-07-03
Volume
393
Issue
1
Pages
51-61
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410166033
Cited by
103
References
17
FWCI
90.14
Type
journal article
Language
en
Open access
green
Funders
NewAmsterdam Pharma (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.